OOIR: Observatory of International Research

Papers

(The TQCC of Cancer Journal is 7. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-11-01 to 2025-11-01.)

Article	Citations
Social Drivers of Cancer Risk and Outcomes Among African American Men	99
Oncology Physician Workforce Diversity	47
PET Imaging of Metabolism, Perfusion, and Hypoxia	42
HER2 and HER3 as Therapeutic Targets in Head and Neck Cancer	25
Toxicities From Antibody-Drug Conjugates	23
Building a Bridge to Equity in Health and Health Care in Cancer Care	22
Poly(ADP-Ribose) Polymerase Inhibitor Inhibition in Ovarian Cancer	21
Clinical Evidence Generation During a Pandemic	21
Health Care Policy and Disparities in Health	21
c-Met Signaling as a Therapeutic Target in Head and Neck Cancer	20
Therapeutic Targeting of FGFR Signaling in Head and Neck Cancer	19
Measurable Residual Disease Assessment as a Surrogate Marker in New Drug Development in Acute Myeloid Leukemia	18
The Principles and Practice of PARP Inhibitor Therapy	16
Stereotactic Body Radiation Therapy	16
Melanoma—Modern Treatment for Metastatic Melanoma	15
Evaluation of the Prognostic Role of Liver Metastases on Patient Outcomes	15
Nonoperative Management for Rectal Cancer	15
Poly(ADP-Ribose) Polymerase Inhibitor Combination Therapy	13
Aurora Kinases as Therapeutic Targets in Head and Neck Cancer	12
Tumor-Infiltrating Lymphocyte and Other Cell Therapies for Metastatic Melanoma	12
Germline Predisposition to Myelodysplastic Syndromes	12
Metastatic Melanoma Treatment in Special Populations	12
Diversity in Cancer Care	12
Antibody Drug Conjugates in Multiple Myeloma	12
Prostate Cancer, Race, and Health Disparity	11

Primary Prevention of Cancer	11
Overlooked and Damaging Impact of Structural Racism and Implicit Bias on US Health Care	11
Hematopoietic Stem Cell Transplantation for Myelodysplastic Syndromes	10
How We Incorporate Venetoclax in Treatment Regimens for Acute Myeloid Leukemia	10
Rectal Cancer—The Only Constant Is Change	10
Current State of Neoadjuvant Therapy for Locally Advanced Rectal Cancer	10
DNA Damage Repair Inhibitors—Combination Therapies	9
Advances in Stereotactic Body Radiation Therapy for Lung Cancer	9
Are We Witnessing a Paradigm Shift in the Treatment of Acute Myeloid Leukemia?	9
Examining the Impact of Tislelizumab Added to Chemotherapy on Health-Related Quality-of-Life Outcomes in Previously Untreated Patients With Nonsquamous Non–Small Cell Lung Cancer	9
Supportive Care for Patients With Myelodysplastic Syndromes	8
New Metabolomic Insights Into Cancer	8
Role of the Microbiome in Immunotherapy of Melanoma	8
Overview of the Management of Higher-Risk Myelodysplastic Syndromes	8
The Clinical Challenges, Trials, and Errors of Combatting Poly(ADP-Ribose) Polymerase Inhibitors Resistance	8
Introduction	8
The Current Role of Human Papillomavirus Circulating Tumor DNA in Oropharynx Cancer	8
Updates in the Management of Uveal Melanoma	8
Effective Personalization of Stereotactic Radiosurgery for Brain Metastases in the Modern Era	8
Short- and Long-term Repercussions of Vancomycin on Immune Surveillance and the Efficacy of Antitumor Treatments	8
Menopausal Hormone Therapy and Breast Cancer	8
A General Approach to Patients Presenting With Locally Advanced or Distant Metastatic Disease	7
Telemedicine and cancer care: Barriers and strategies to optimize delivery: Erratum	7
Evolution of Therapy for Older Patients With Acute Myeloid Leukemia	7
How Far We’ve Come	7
PI3K Inhibition for Squamous Cell Head and Neck Carcinoma	7
Impact of Precision Medicine in Oncology	7
Discovery of Natural Products for Cancer Prevention	7